Bonal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bonal

Property Description
Active Ingredient Sodium Hyaluronate (Hyaluronan)
Form Sterile Solution for Intra-Articular Injection
Pharmacological Class Viscosupplementation Agent
Common Use Restoring joint fluid properties (Lubrication/Cushioning)
Origin Endogenous Substance Derivative (Biocompatible)

Bonal is a prescription-only medicine administered as a sterile solution for injection, primarily classified as a Viscosupplementation Agent. It is designed to physically restore and improve the necessary viscoelastic qualities of the fluid found within the body's joints. Due to its primary role in providing mechanical support rather than a systemic chemical action, this type of preparation is functionally distinct from traditional drugs. The regulatory classification of Sodium Hyaluronate preparations in the United States often places them in the category of advanced medical devices, based on the rationale that their main function is physical and not metabolic.

Composition: Sodium Hyaluronate and Endogenous Origin

The sole active ingredient in Bonal is Sodium Hyaluronate, which is the salt derivative of Hyaluronic acid (Hyaluronan). Hyaluronan is a large, naturally occurring polysaccharide and a type of Glycosaminoglycan (GAG) that is a key component in human tissues. This confirms that Bonal is an endogenous substance derivative, meaning its core component is biochemically identical or highly similar to a substance already present in the body's joint fluid, contributing to its biocompatible nature.

General Purpose: Joint Lubrication and Viscoelastic Support

The general purpose of Bonal is to provide exogenous supplementation of the joint's essential lubricating and cushioning properties through the process known as viscosupplementation. This mechanism is clinically recognized for directly addressing the physical degradation of the synovial fluid. The fluid's restored ability to act as an effective joint lubricant and shock absorber aims to improve the joint’s mechanical function to alleviate stiffness and discomfort and facilitate smoother joint movement.

Regulatory References

  1. NIH Drug Classifications

What side effects are possible with Bonal?

Possible Side Effects and Safety Information

Bonal, a combination product, is associated with a range of adverse effects and serious warnings documented in official government regulatory labeling, such as that provided by the U.S. Food and Drug Administration (FDA).

Serious Regulatory Warnings

Official labeling includes a Boxed Warning highlighting critical risks, including:

  • Life-Threatening Respiratory Depression: Serious or fatal slowing of breathing may occur, particularly when therapy is initiated or the dose is increased.
  • Hepatotoxicity (Acute Liver Failure): The Acetaminophen component is associated with acute liver failure, sometimes leading to liver transplant or death, especially with high daily doses.
  • Addiction, Abuse, and Misuse: Due to the Codeine and Butalbital components, the medication carries risks of addiction, abuse, and misuse, which can lead to overdose and death.
  • Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged use during pregnancy can result in this life-threatening condition in the newborn.

Frequently Reported Adverse Reactions

The following effects are frequently reported in regulatory documentation, grouped by the affected system:

System Organ Class Adverse Reactions (Examples)
Nervous System Drowsiness, Lightheadedness, Sedation, Dizziness
Gastrointestinal Nausea, Vomiting, Abdominal pain
Other Intoxicated feeling, Shortness of breath, Confusion (mild)

Population-Specific Safety Constraints

Regulatory documents outline specific restrictions for certain groups:

  • Pediatric Use: The product is contraindicated in children younger than 12 years of age and in children younger than 18 years following tonsillectomy and/or adenoidectomy.
  • Pregnancy/Lactation: Breastfeeding is not recommended, and prolonged use in pregnancy carries the risk of NOWS.
  • Geriatric Patients: Older adults are at increased risk of respiratory depression.

General Safety Restrictions

Bonal is officially contraindicated in patients with a known hypersensitivity to its components and in those with Porphyria. Furthermore, the medication may impair mental and physical abilities required for operating machinery or driving.

Overdose and Emergency Response

Overdose with Bonal, a combination product, presents specific, officially documented risks derived from its components, primarily the opioid and barbiturate agents and acetaminophen.

Documented Overdose Manifestations

The regulatory prescribing information documents severe clinical signs including profound sedation, confusion, coma, and irregular or shallow breathing. Other documented symptoms involve the liver, where signs of acute toxicity may present as nausea, vomiting, jaundice, and pain in the upper right part of the stomach.

Severe Outcomes and Emergency Action

Official regulatory sources explicitly warn that life-threatening respiratory depression, acute liver failure, and fatal overdose are potential outcomes. Immediate medical attention is required upon any suspected overdose, or if an amount exceeding the maximum daily dose of acetaminophen is ingested, even if the individual feels well.

Emergency services must be contacted immediately if the individual collapses, has a seizure, or exhibits severe difficulty breathing. The label documents that the opioid component's toxicity can be addressed by the administration of Naloxone as an emergency supportive measure.

Population-Specific Overdose Notes

The regulatory information notes that accidental ingestion of even one dose carries a risk of fatal overdose for children. The risk of severe symptoms is also heightened for those identified as ultra-rapid metabolizers of codeine and when the medication is taken concurrently with other CNS depressants.

Therapeutic Uses of Bonal

Quick Facts

  • Main Therapeutic Area: Tension (or muscle contraction) headaches.
  • Role in Management: Used for managing the symptom complex of certain headaches.
  • Application: A therapeutic option when non-opioid and alternative treatments are insufficient.

Bonal is an established combination medication used in the management of specific types of pain. Its primary therapeutic application is to address the symptom complex associated with tension headaches, also known as muscle contraction headaches. It is reserved as a viable treatment option when other non-opioid pain relievers and alternative approaches do not adequately address the patient's condition.

This medication may help provide relief from the discomfort and accompanying symptoms of the headache. The components of this formulation are recognized to address pain perception and contribute to relaxation in the central nervous system, thereby supporting the overall therapeutic goal of symptom management.

Bonal is prescribed as part of a comprehensive management plan. A patient's care team will determine if Bonal is appropriate to use based on their specific severity of pain and prior treatment history. For detailed information regarding the approved indications and complete risk profile, official information is available for this product's combination of active ingredients.

Healthcare professionals will monitor patient response closely to ensure therapeutic benefit and proper use.

Eligibility and Restrictions for Use

The official eligibility profile for Bonal (Butalbital, Acetaminophen, Caffeine, and Codeine) strictly defines patient groups who can or cannot use the medicine, based on government regulatory labeling.

Contraindicated Populations

Use is absolutely prohibited for:

  • Children younger than 12 years of age.
  • Children younger than 18 following tonsillectomy or adenoidectomy.
  • Patients with porphyria, significant respiratory depression, or severe bronchial asthma.
  • Individuals with known hypersensitivity to any component.

Eligibility by Age and Condition

Scope Eligibility Status (Regulatory Wording)
Pediatric Use Contraindicated under 12 years; use not established under 12.
Geriatric Patients Use with caution and monitor closely.
Hepatic / Renal Impairment Use with caution in severe impairment.
Pregnancy Prolonged use not recommended due to risk of Neonatal Opioid Withdrawal Syndrome (NOWS).
Lactation Not recommended due to risk of serious adverse reactions in the infant.

Additional Restrictions

Use must be avoided in patients who are ultra-rapid metabolizers of Codeine (CYP2D6) and in adolescents (12-18 years) with high respiratory risk factors. The use of Bonal is confined to adults and adolescents over 12 who meet the specific labeled conditions and have none of the absolute contraindications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bonal's interaction profile is based on the components Butalbital, Acetaminophen, Caffeine, and Codeine, with constraints strictly defined in regulatory documents.


Contraindicated Combinations and Substances

  • Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs is contraindicated, including use within 14 days of taking an MAOI.
  • Other Central Nervous System (CNS) Depressants: Co-administration with substances like alcohol, benzodiazepines, and other opioids may cause additive CNS depressant effects, resulting in profound sedation and respiratory depression.

Pharmacokinetic and Pharmacodynamic Interactions

Mechanism Type Interacting Substance Categories Official Interaction Statement
Pharmacokinetic CYP2D6 Inhibitors (e.g., Quinidine) May reduce the formation of the active metabolite, Morphine, potentially reducing the analgesic effect.
Pharmacokinetic CYP3A4 Inhibitors (e.g., Grapefruit Juice) May increase Codeine plasma concentrations, which could increase the risk of adverse effects.
Pharmacodynamic Serotonergic Drugs (e.g., SSRIs, Triptans) Concurrent use may result in the development of Serotonin Syndrome.
Pharmacodynamic Other Acetaminophen Products Increases the risk of hepatotoxicity and must be avoided to prevent exceeding the maximum daily dose.

Population-Specific Notes

  • The official label includes a specific consideration for individuals identified as Codeine Ultra-Rapid Metabolizers (CYP2D6 imes 2 genotype), who may experience higher-than-expected serum Morphine levels.

Regulatory documents formally define this interaction structure by categorizing agents that modify Codeine metabolism and listing substances that cause additive CNS depression with the Butalbital and Codeine components. This establishes constraints, including the mandatory 14-day separation rule for MAOIs and strict avoidance of other acetaminophen-containing products.

Mechanism of Action

How Bonal Works

Bonal modulates cellular signaling through its interaction with two distinct molecular domains, influencing overall neuronal function. The drug's pharmacodynamic mechanism is classified by its activity at ion channels and specific neurotransmitter receptors.

Ion Channel Signaling Modulation

This domain involves the drug's effect on voltage-gated sodium channels within the central nervous system. Bonal modifies the function of these channels, inducing conformational changes that favor the inactive state. This molecular effect limits the sustained, rapid firing of neurons, which is a high-frequency firing pattern observed across multiple signaling networks. This ultimately functions to limit the rate of sustained neuronal firing.

GABAA Receptor Positive Allosteric Modulation

Bonal also acts on pathways involving the GABAA receptor, which is central to inhibitory signaling. It functions as a positive allosteric modulator, enhancing the conductance mediated by the body's natural inhibitory ligand. This engagement supports the reinforcement of inhibitory signaling within targeted pathways by increasing chloride flux, thereby decreasing the downstream influence of the associated mediators, resulting in an overall shift toward diminished neuronal excitability.

Dosage and Administration Information

How Bonal is Used: Official Administration Guidelines

Bonal, a combination medicine containing Butalbital, Acetaminophen, Caffeine, and Codeine, is prescribed for use only under specific conditions as outlined in official documentation. Its administration protocol is designed for acute pain management with strict limits on frequency and duration, reflecting the requirement to use the Lowest Effective Dosage (LED) for the shortest period possible.

Administration Scope

Category Official Instruction
Route of Administration The product is taken exclusively by the oral route, typically as a capsule.
Standard Dosing The usual adult dose is one or two capsules at the onset of pain, as determined by a healthcare provider.
Frequency & Ceiling Dosing may be repeated every 4 hours as needed (PRN). The maximum daily dose must not exceed 6 capsules.

Use Restrictions and Special Populations

Use is constrained to acute episodes; official information does not support the efficacy or safety of this product for managing multiple recurrent headaches.

Age-Group Rules:

  • Pediatric Patients: This medication is contraindicated in children younger than 12 years of age and in those younger than 18 years following tonsillectomy and/or adenoidectomy.
  • Older Adults: Dose selection should be cautious, and dosing is generally initiated at the low end of the dosing range.

Discontinuation

To prevent potential withdrawal symptoms in physically dependent patients, Bonal must not be discontinued abruptly. The dosage should be tapered gradually under professional supervision.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bonal

The official research evidence for Bonal (a combination of Butalbital, Acetaminophen, Caffeine, and Codeine) is primarily focused on how it was evaluated in research exploring the symptom complex associated with tension headaches. The evidence base comes mainly from Randomized Controlled Trials (RCTs) and systematic reviews, which are the study designs primarily used in regulatory assessments. This research contributes to the broader evidence landscape by describing patterns observed in the studies conducted by scientists.


Evidence for Managing Symptoms of Tension Headaches

Research has examined Bonal in the context of studies assessing episodic or acute changes related to tension headaches. The main research design was studied for its short-term use during episodes where symptoms become more noticeable. In these trials, researchers examined a specific population of adults who experienced recurring tension-type headaches and who were monitored over defined time intervals.

Studies monitored outcomes related to physical discomfort, primarily by using standardized tools to measure the change in headache pain intensity following the dose. Controlled trials report on patterns measured in the groups that received the study product compared to those receiving the placebo. While the research provides insight into short-term changes, the findings describing sustained symptom changes over longer periods were mixed or less uniformly reported.


Long-Term Studies and Follow-up

The majority of pivotal studies are relevant in trials assessing short-term or episodic symptom patterns. The duration of follow-up in the most rigorous controlled trials was limited, typically to a few weeks or months. This means that long-term effects are not fully established or characterized by the existing evidence.

Because Bonal may be associated with a risk of creating headaches if used too frequently over time (known as medication overuse headache), research protocols for long-term trials are challenging to design, and ethical considerations often limit the duration for which patients were observed in controlled settings. Consequently, there is limited information for long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Bonal (FAQ)

Q: If I miss a dose of Bonal, what generally happens?

Official guidance typically describes a standard approach for missed doses, where it is taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the approach described is usually to skip the missed dose and return to the regular schedule, which helps avoid taking doses too close together. This guidance helps prevent accidentally exceeding the maximum daily dose.

Q: What happens if I stop taking Bonal suddenly?

Because Bonal contains Butalbital and Codeine, official documents state that abrupt discontinuation, especially after prolonged use, is not recommended. Stopping suddenly may result in withdrawal symptoms such as muscle pain, sweating, or restlessness. Regulatory information emphasizes that the dosage must be tapered gradually under professional supervision to prevent this outcome.

Q: Can Bonal make other medications work differently?

Yes, official regulatory documents indicate that Bonal can interact with other drugs. Its components may cause additive effects when combined with central nervous system (CNS) depressants, or they can affect how other medications are processed by the body (metabolized). This necessitates adherence to official warnings regarding specific contraindicated drug combinations.

Q: What are the concerns about Bonal and driving?

The official labeling includes a warning that this medication may impair the mental and physical abilities needed to perform potentially hazardous tasks, such as driving a car or operating machinery. This warning is related to the drug's properties as a central nervous system depressant, which may result in effects like drowsiness and lightheadedness.

Q: Is it possible to develop a tolerance to Bonal over time?

Official documentation notes that both the Butalbital and Codeine components may be habit-forming. Extended use can lead to physical dependence, which is often related to the body developing a tolerance to the drug's effects. The presence of physical dependence may result in withdrawal symptoms if the medication is discontinued abruptly.

Q: What is the active ingredient in Bonal?

Bonal is officially defined as a combination product. According to regulatory documents, it contains four distinct active ingredients: Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate.

Q: How is Bonal similar to or different from other drugs in its class?

Bonal is a combination product that includes Codeine, which is classified as an opioid analgesic, and Butalbital, which is a type of short- to intermediate-acting barbiturate. Official labels define its components by their respective pharmacological classes, meaning it shares features with both drug types.

Q: Are there any common foods that can affect Bonal?

Official documents specifically identify that some substances can affect how Bonal is metabolized in the body. For instance, Grapefruit juice is listed because it can affect the body's processing of Codeine, potentially increasing its plasma concentrations. Other food interactions are not uniformly listed in the regulatory label.

Q: How long does it typically take to feel the effects of Bonal?

Regulatory information indicates that the Butalbital component is readily absorbed from the digestive system. The time to reach peak plasma concentrations is generally reported to be about two hours, which suggests when the effects of the combination product are most prominent.

Q: Is it common to have stomach upset when first starting Bonal?

Gastrointestinal reactions are listed among the frequently reported adverse reactions in official regulatory documentation. These include issues like nausea, vomiting, and abdominal pain.

Q: What kind of studies have been done on Bonal?

The regulatory evidence base for Bonal is primarily focused on studies related to the relief of the symptom complex of tension headache. These studies are generally used to assess the product's use for acute, short-term episodes.

Q: Does Bonal interact with common over-the-counter medicines?

Yes, regulatory warnings state that Bonal must not be taken with any other product containing Acetaminophen, which is found in many common over-the-counter (OTC) medicines. Combining these products significantly increases the risk of severe liver damage (hepatotoxicity).

Q: How quickly does Bonal leave the body?

The elimination time of Bonal varies by component. Pharmacokinetic data indicates that the Codeine and Caffeine components have a shorter half-life (around 3 hours), but the Butalbital component has a longer half-life, approximately 35 hours, meaning it takes the longest to be fully eliminated from the body.

Q: Can Bonal affect fertility or reproductive health?

Official documentation does not typically include reproductive or fertility studies for combination products like Bonal. However, a specific warning exists regarding its use in pregnancy: prolonged use is associated with the risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn.

Q: Are there any specific laboratory tests required before starting Bonal?

Regulatory guidance and patient information indicate that a healthcare provider may order blood and urine tests to monitor progress, especially when the medication is first started. These tests are used as a means of monitoring progress and checking for potential unwanted effects during treatment.

Q: Does Bonal interact with any herbal products?

Official warnings specifically advise caution with any substances that can affect certain liver enzymes or increase the risk of Serotonin Syndrome. Some herbal products may interact via these mechanisms, although specific products are not routinely listed in the regulatory label.

Q: Is Bonal known to cause mood swings?

Official side effect lists note that central nervous system reactions such as mental confusion, excitement, or depression may occur. These central nervous system reactions are sometimes observed, potentially related to drug intolerance or overdosage.

Q: What is the shelf life of Bonal tablets?

While official storage instructions advise users not to keep outdated medicine, the specific shelf life or expiration date is a manufacturing detail. This date is printed on the individual product packaging and is not part of the general regulatory labeling information.

Q: Does Bonal show up on standard drug tests?

Bonal contains Butalbital (a barbiturate) and Codeine (an opioid). Both of these are regulated substances. The presence of these components or their breakdown products (metabolites) may be detectable in certain drug screening processes.

Q: Can Bonal affect blood pressure readings?

The official warnings for the codeine component mention the possibility of a hypotensive reaction (low blood pressure) and severe hypotension, especially in certain clinical settings. This indicates that the medication may affect blood pressure and that it could require monitoring.

Q: Have there been any recent updates to the official Bonal warnings?

The FDA continues to issue guidance related to the Acetaminophen component, such as warnings about the risk of rare but serious skin reactions (like SJS and TEN) with products containing Acetaminophen. These updates apply to combination products like Bonal.

How should Bonal be stored and disposed of?

How to Store and Dispose of Bonal

Bonal, a medication containing Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate, must be stored under specific environmental and security conditions as required by regulatory labeling.

Storage and Handling

Requirement Details
Temperature Store at controlled room temperature, typically 68 F to 77 F (20 C to 25 C).
Protection Keep the medicine protected from moisture, excess heat, and direct light, and prevent it from freezing.
Security The medication must be kept securely and out of the sight and reach of children and pets in its original, tightly closed container.

Disposal Instructions

As a controlled substance, Bonal must be disposed of following official guidelines to prevent misuse. The primary method is returning unused or expired medication to an authorized drug take-back program or DEA-registered collector. If a take-back option is unavailable, the product must be mixed with an undesirable substance, sealed in a container, and then placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bonal found in:

A-Z Index: